Searchable abstracts of presentations at key conferences in endocrinology

ea0034p146 | Clinical practice/governance and case reports | SFEBES2014

Delayed hypocalcaemia following treatment of malignant hypercalcaemia with denosumab

Puttanna Amar , Khan Ahsan , Padinjakara Noushad

Denosumab is a MAB currently licensed for use in treatment of osteoporosis. It is designed to inhibit RANK ligand to prevent bone breakdown by osteoclasts. Its use for treatment of malignant hypercalcaemia is still to be fully investigated.We present the case of a 71-year-old south Asian gentleman with recurrent resistant hypercalcaemia secondary to follicular non-HodgkinÂ’s lymphoma. Calcitriol levels were elevated which was thought to be lymphoma r...